Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.

Link to article at PubMed

Related Articles

Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.

J Am Coll Cardiol. 2013 Jun 6;

Authors: Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Køber L, Torp-Pedersen C, Hansen ML

Abstract
OBJECTIVES: To investigate the risk of thrombosis and bleeding according to multiple antithrombotic treatment regimens in atrial fibrillation (AF) patients after myocardial infarction (MI) or percutaneous coronary intervention (PCI) BACKGROUND: The optimal antithrombotic treatment strategy is unresolved in patients with multiple indications. METHODS: A total of 12,165 AF patients hospitalized with MI and/or undergoing PCI between 2001-2009 were identified by nationwide registries (60.7% males, mean age 75.6 years). Risk of MI/coronary death, ischemic stroke, and bleeding according to antithrombotic treatment regimen was estimated by Cox regression models. RESULTS: Within one year, MI or coronary death, ischemic stroke, and bleeding events occurred in 2,255 (18.5%), 680 (5.6%), and 769 (6.3%) patients, respectively. Relative to triple therapy (oral anticoagulation (OAC) + aspirin + clopidogrel), no increased risk of recurrent coronary events was seen for OAC + clopidogrel (hazard ratio [HR] 0.69 [0.48-1.00]), OAC + aspirin (HR 0.96 [0.77-1.19]), or aspirin + clopidogrel (HR 1.17 [0.96-1.42]), but aspirin + clopidogrel resulted in a higher risk of ischemic stroke (HR 1.50 [1.03-2.20]). Also, OAC + aspirin and aspirin + clopidogrel were associated with a significant increased risk of all-cause death (HR 1.52 [1.17-1.99] and 1.60 [1.25-2.05]). When compared to triple therapy, bleeding risk was non-significantly reduced for OAC + clopidogrel (HR 0.78 [0.55-1.12]) and significantly reduced for OAC + aspirin and aspirin + clopidogrel. CONCLUSION: In real-life AF patients with indication for multiple antithrombotic drugs after MI/PCI, OAC and clopidogrel was equal or better on both benefit and safety outcomes compared to triple therapy.

PMID: 23747760 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.